C4 Therapeutics Inc reports results for the quarter ended in September 30 - Earnings Summary

• C4 Therapeutics Inc CCCC.OQ reported a quarterly adjusted loss of 35 cents​​ per share for the quarter ended September 30, higher than the same quarter last year, when the company reported EPS of -52 cents. The mean expectation of seven analysts for the quarter was for a loss of 38 cents per share. Wall Street expected results to range from -46 cents to -28 cents per share.

• Revenue rose 38.7% to $15.36 million from a year ago; analysts expected $4.60 million.

• C4 Therapeutics Inc's reported EPS for the quarter was a loss of 35 cents​.

• The company reported a quarterly loss of $24.67 million.

• C4 Therapeutics Inc shares had fallen by 3.0% this quarter and lost 2.1% so far this year.

FORECAST CHANGES

• The mean earnings estimate of analysts had risen by about 1.3% in the last three months.​

• In the last 30 days, there have been no earnings estimate revisions by analysts covering the company.

RECOMMENDATIONS

• The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 5 "strong buy" or "buy," 3 "hold" and no "sell" or "strong sell."

• The average consensus recommendation for the biotechnology & medical research peer group is also "buy"

Wall Street's median 12-month price target for C4 Therapeutics Inc is 14.00

This summary was machine generated from LSEG data November 1 at 03:38 a.m. UTC. ​All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)